RUNX2 and neoplasm: The tumour microenvironment, such as matrix stiffness and composition, activate mechanotransduction pathways (e.g., integrin–FAK, YAP/TAZ) that promote EMT and metabolic reprogramming, processes intersecting with RUNX2–sterol regulatory element-binding protein 1 (SREBP1) signaling.